Peer-reviewed veterinary case report
Oral rosiglitazone with carboplatin tested in dogs with cancer
By Allstadt Frazier, S et al.·Published in Veterinary and comparative oncology·2014·Veterinary Medical Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
- Species:
- dog
Plain-English summary
Seven dogs with cancer were given a combination of oral rosiglitazone, an antidiabetic medication that may help slow tumor growth, and carboplatin, a common chemotherapy drug. The goal was to find the highest safe dose of rosiglitazone and to monitor any side effects. Some dogs experienced mild to moderate liver enzyme increases, but overall, the treatment was manageable without severe complications. This study helps understand how these medications can be used together in treating cancer in dogs.
People also search for: dog cancer treatment options · rosiglitazone for dogs · carboplatin side effects in dogs
Abstract
Rosiglitazone is an FDA-approved peroxisome proliferator-activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to determine the maximally tolerated dose, peak plasma concentrations and side effect profile of oral rosiglitazone when combined with carboplatin in dogs with cancer. Rosiglitazone was administered at 6 and 8 mg/m(2) to seven dogs. Carboplatin was administered at 240-300 mg/m(2) in combination with rosiglitazone. For toxicity evaluation, the toxicity data for the seven dogs in this study were combined with the toxicity data from three dogs previously reported in a methodology study. Peak plasma rosiglitazone concentrations varied with dose. The dose-limiting toxicity was hepatic at a dose of 8 mg/m(2). Three dogs had mild to moderate alanine aminotransferase elevations but no changes in total bilirubin, alkaline phosphatase, blood glucose or γ-glutamyltranspeptidase values were noted.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22364238/